Penumbra Inc
NYSE:PEN
Intrinsic Value
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. [ Read More ]
The intrinsic value of one PEN stock under the Base Case scenario is 95.594 USD. Compared to the current market price of 204.115 USD, Penumbra Inc is Overvalued by 53%.
Valuation Backtest
Penumbra Inc
Run backtest to discover the historical profit from buying and selling PEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Penumbra Inc
Current Assets | 915.4m |
Cash & Short-Term Investments | 289.2m |
Receivables | 201.8m |
Other Current Assets | 424.4m |
Non-Current Assets | 640.9m |
PP&E | 292.5m |
Intangibles | 237.3m |
Other Non-Current Assets | 111m |
Current Liabilities | 151.1m |
Accounts Payable | 27.2m |
Accrued Liabilities | 114.8m |
Other Current Liabilities | 9.2m |
Non-Current Liabilities | 226.2m |
Long-Term Debt | 23.7m |
Other Non-Current Liabilities | 202.5m |
Earnings Waterfall
Penumbra Inc
Revenue
|
1.1B
USD
|
Cost of Revenue
|
-375.9m
USD
|
Gross Profit
|
682.6m
USD
|
Operating Expenses
|
-590.9m
USD
|
Operating Income
|
91.8m
USD
|
Other Expenses
|
-812k
USD
|
Net Income
|
91m
USD
|
Free Cash Flow Analysis
Penumbra Inc
What is Free Cash Flow?
PEN Profitability Score
Profitability Due Diligence
Penumbra Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Penumbra Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
PEN Solvency Score
Solvency Due Diligence
Penumbra Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Penumbra Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PEN Price Targets Summary
Penumbra Inc
According to Wall Street analysts, the average 1-year price target for PEN is 284.815 USD with a low forecast of 242.4 USD and a high forecast of 336 USD.
Ownership
PEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PEN Price
Penumbra Inc
Average Annual Return | 18% |
Standard Deviation of Annual Returns | 35.06% |
Max Drawdown | -63% |
Market Capitalization | 7.9B USD |
Shares Outstanding | 39 291 044 |
Percentage of Shares Shorted | 7.08% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. The company is headquartered in Alameda, California and currently employs 3,800 full-time employees. The company went IPO on 2015-09-18. The firm designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. The company is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. The company is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. The company has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The firm's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, and Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one PEN stock under the Base Case scenario is 95.594 USD.
Compared to the current market price of 204.115 USD, Penumbra Inc is Overvalued by 53%.